Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Return on Capital Employed (2016 - 2025)

Sunshine Biopharma's Return on Capital Employed history spans 10 years, with the latest figure at 0.26% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 2.0% year-over-year to 0.26%; the TTM value through Dec 2025 reached 0.26%, down 2.0%, while the annual FY2025 figure was 0.26%, 0.0% changed from the prior year.
  • Return on Capital Employed reached 0.26% in Q4 2025 per SBFM's latest filing, up from 0.26% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.1% in Q3 2022 to a low of 3.09% in Q1 2021.
  • Average Return on Capital Employed over 5 years is 0.73%, with a median of 0.26% recorded in 2025.
  • Peak YoY movement for Return on Capital Employed: crashed -390bps in 2021, then surged 278bps in 2022.
  • A 5-year view of Return on Capital Employed shows it stood at 1.08% in 2021, then grew by 11bps to 0.96% in 2022, then skyrocketed by 77bps to 0.22% in 2023, then decreased by -10bps to 0.24% in 2024, then fell by -7bps to 0.26% in 2025.
  • Per Business Quant, the three most recent readings for SBFM's Return on Capital Employed are 0.26% (Q4 2025), 0.26% (Q3 2025), and 0.26% (Q2 2025).